{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,15]],"date-time":"2026-10-15T10:22:20Z","timestamp":1792059740616,"version":"4.4.0"},"reference-count":87,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2022,7,1]],"date-time":"2022-07-01T00:00:00Z","timestamp":1656633600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,7,1]],"date-time":"2022-07-01T00:00:00Z","timestamp":1656633600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2022,1,10]],"date-time":"2022-01-10T00:00:00Z","timestamp":1641772800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","journalofsubstanceabusetreatment.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Substance Abuse Treatment"],"published-print":{"date-parts":[[2022,7]]},"DOI":"10.1016\/j.jsat.2021.108717","type":"journal-article","created":{"date-parts":[[2021,12,30]],"date-time":"2021-12-30T11:38:24Z","timestamp":1640864304000},"page":"108717","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":68,"special_numbering":"C","title":["A systematic literature review of clinical trials and therapeutic applications of ibogaine"],"prefix":"10.1016","volume":"138","author":[{"given":"Patrick","family":"K\u00f6ck","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Katharina","family":"Froelich","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marc","family":"Walter","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Undine","family":"Lang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kenneth M.","family":"D\u00fcrsteler","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"1","key":"10.1016\/j.jsat.2021.108717_bb0005","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1007\/s12012-015-9311-5","article-title":"hERG blockade by iboga alkaloids","volume":"16","author":"Alper","year":"2016","journal-title":"Cardiovascular Toxicology"},{"key":"10.1016\/j.jsat.2021.108717_bb0010","first-page":"1","article-title":"Ibogaine: a review. The alkaloids","volume":"56","author":"Alper","year":"2001","journal-title":"Chemistry and Biology"},{"issue":"3","key":"10.1016\/j.jsat.2021.108717_bb0015","doi-asserted-by":"crossref","first-page":"234","DOI":"10.1080\/105504999305848","article-title":"Treatment of acute opioid withdrawal with ibogaine","volume":"8","author":"Alper","year":"1999","journal-title":"The American Journal on Addictions"},{"key":"10.1016\/j.jsat.2021.108717_bb0020","doi-asserted-by":"crossref","first-page":"257","DOI":"10.1111\/j.1749-6632.2000.tb06687.x","article-title":"Ibogaine in acute opioid withdrawal. An open label case series","volume":"909","author":"Alper","year":"2000","journal-title":"Annals of the New York Academy of Sciences"},{"issue":"1","key":"10.1016\/j.jsat.2021.108717_bb0025","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1016\/j.jep.2007.08.034","article-title":"The ibogaine medical subculture","volume":"115","author":"Alper","year":"2008","journal-title":"Journal of Ethnopharmacology"},{"issue":"2","key":"10.1016\/j.jsat.2021.108717_bb0030","doi-asserted-by":"crossref","first-page":"398","DOI":"10.1111\/j.1556-4029.2011.02008.x","article-title":"Fatalities temporally associated with the ingestion of ibogaine","volume":"57","author":"Alper","year":"2012","journal-title":"Journal of Forensic Sciences"},{"issue":"10","key":"10.1016\/j.jsat.2021.108717_bb0035","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0077262","article-title":"Effect of iboga alkaloids on micro-opioid receptor-coupled G protein activation","volume":"8","author":"Antonio","year":"2013","journal-title":"PloS One"},{"issue":"9","key":"10.1016\/j.jsat.2021.108717_bb0040","doi-asserted-by":"crossref","first-page":"1525","DOI":"10.1016\/j.biocel.2010.05.011","article-title":"Interaction of ibogaine with human alpha3beta4-nicotinic acetylcholine receptors in different conformational states","volume":"42","author":"Arias","year":"2010","journal-title":"The International Journal of Biochemistry & Cell Biology"},{"key":"10.1016\/j.jsat.2021.108717_bb0045","doi-asserted-by":"crossref","DOI":"10.1016\/j.drugpo.2020.102857","article-title":"Ibogaine therapy for addiction: Consumer views from online fora","volume":"83","author":"Barber","year":"2020","journal-title":"International Journal of Drug Policy"},{"key":"10.1016\/j.jsat.2021.108717_bb0050","series-title":"Progress in Brain Research","doi-asserted-by":"crossref","DOI":"10.1016\/bs.pbr.2018.08.002","article-title":"A case report SPECT study and theoretical rationale for the sequential administration of ibogaine and 5-MeO-DMT in the treatment of alcohol use disorder","volume":"242","author":"Barsuglia","year":"2018"},{"key":"10.1016\/j.jsat.2021.108717_bb0055","series-title":"Life after Ibogaine","author":"Bastiaans","year":"2004"},{"key":"10.1016\/j.jsat.2021.108717_bb0060","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1016\/S0099-9598(01)56009-5","article-title":"Comparative neuropharmacology of ibogaine and its O-desmethyl metabolite, noribogaine","volume":"56","author":"Baumann","year":"2001","journal-title":"The Alkaloids. Chemistry and Biology"},{"key":"10.1016\/j.jsat.2021.108717_bb0065","article-title":"Mixed Kappa\/Mu partial opioid agonists as potential treatments for cocaine dependence","volume":"Vol. 69","author":"Bidlack","year":"2014"},{"key":"10.1016\/j.jsat.2021.108717_bb0070","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1007\/164_2019_304","article-title":"Clinical trials for opioid use disorder","volume":"258","author":"Blessing","year":"2020","journal-title":"Handbook of Experimental Pharmacology"},{"key":"10.1016\/j.jsat.2021.108717_bb0075","doi-asserted-by":"crossref","first-page":"250","DOI":"10.1016\/j.pnpbp.2015.03.002","article-title":"Classic hallucinogens in the treatment of addictions","volume":"64","author":"Bogenschutz","year":"2016","journal-title":"Progress in Neuro-Psychopharmacology and Biological Psychiatry"},{"key":"10.1016\/j.jsat.2021.108717_bb0080","series-title":"Behavioral neurobiology of psychedelic drugs","first-page":"361","article-title":"Therapeutic Applications of Classic Hallucinogens","author":"Bogenschutz","year":"2018"},{"issue":"1","key":"10.1016\/j.jsat.2021.108717_bb0085","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1080\/00952990.2017.1320802","article-title":"Treatment of opioid use disorder with ibogaine: Detoxification and drug use outcomes","volume":"44","author":"Brown","year":"2018","journal-title":"American Journal of Drug and Alcohol Abuse"},{"issue":"2","key":"10.1016\/j.jsat.2021.108717_bb0090","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1080\/02791072.2019.1598603","article-title":"Ibogaine and subjective experience: Transformative states and psychopharmacotherapy in the treatment of opioid use disorder","volume":"51","author":"Brown","year":"2019","journal-title":"Journal of Psychoactive Drugs"},{"issue":"August","key":"10.1016\/j.jsat.2021.108717_bb0095","first-page":"1","article-title":"Combination psychedelic therapy to treat substance use disorders: Insights from human and rodent studies","volume":"236","author":"Calvey","year":"2020","journal-title":"Journal of Anatomy"},{"key":"10.1016\/j.jsat.2021.108717_bb0100","article-title":"A non-hallucinogenic psychedelic analogue with therapeutic potential","volume":"January","author":"Cameron","year":"2020","journal-title":"Nature"},{"issue":"4","key":"10.1016\/j.jsat.2021.108717_bb0105","doi-asserted-by":"crossref","first-page":"424","DOI":"10.1111\/j.1369-1600.2010.00251.x","article-title":"Noribogaine, but not 18-MC, exhibits similar actions as ibogaine on GDNF expression and ethanol self-administration","volume":"15","author":"Carnicella","year":"2010","journal-title":"Addiction Biology"},{"issue":"3","key":"10.1016\/j.jsat.2021.108717_bb0110","doi-asserted-by":"crossref","first-page":"214","DOI":"10.1080\/02791072.2016.1180467","article-title":"Remission of severe opioid use disorder with ibogaine: A case report","volume":"48","author":"Cloutier-Gill","year":"2016","journal-title":"Journal of Psychoactive Drugs"},{"key":"10.1016\/j.jsat.2021.108717_bb0115","series-title":"Progress in brain research","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1016\/bs.pbr.2018.08.005","article-title":"Ibogaine as a treatment for substance misuse: Potential benefits and practical dangers","volume":"242","author":"Corkery","year":"2018"},{"issue":"February","key":"10.1016\/j.jsat.2021.108717_bb0120","doi-asserted-by":"crossref","first-page":"46","DOI":"10.1016\/j.jsat.2018.06.010","article-title":"Symptoms of anhedonia, not depression, predict the outcome of treatment of cocaine dependence","volume":"92","author":"Crits-Christoph","year":"2018","journal-title":"Journal of Substance Abuse Treatment"},{"key":"10.1016\/j.jsat.2021.108717_bb0125","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1016\/j.jep.2016.06.036","article-title":"Tabernaemontana catharinensis ethyl acetate fraction presents antinociceptive activity without causing toxicological effects in mice","volume":"191","author":"da Silva Brum","year":"2016","journal-title":"Journal of Ethnopharmacology"},{"key":"10.1016\/j.jsat.2021.108717_bb0130","doi-asserted-by":"crossref","DOI":"10.1177\/2470547020939564","article-title":"Psychedelic treatment for trauma-related psychological and cognitive impairment among US special operations forces veterans","volume":"4","author":"Davis","year":"2020","journal-title":"Chronic Stress"},{"issue":"2","key":"10.1016\/j.jsat.2021.108717_bb0135","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1556\/2054.01.2017.009","article-title":"Subjective effectiveness of ibogaine treatment for problematic opioid consumption: Short- and long-term outcomes and current psychological functioning","volume":"1","author":"Davis","year":"2017","journal-title":"Journal of Psychedelic Studies"},{"issue":"4","key":"10.1016\/j.jsat.2021.108717_bb0140","doi-asserted-by":"crossref","first-page":"287","DOI":"10.1080\/02791072.2018.1487607","article-title":"A mixed-method analysis of persisting effects associated with positive outcomes following ibogaine detoxification","volume":"50","author":"Davis","year":"2018","journal-title":"Journal of Psychoactive Drugs"},{"key":"10.1016\/j.jsat.2021.108717_bb0145","series-title":"Clinical guidelines for ibogaine-assisted detoxification","author":"Dickinson","year":"2016"},{"issue":"1","key":"10.1016\/j.jsat.2021.108717_bb0150","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1556\/2054.01.2016.001","article-title":"The antiaddictive effects of ibogaine: A systematic literature review of human studies","volume":"1","author":"dos Santos","year":"2016","journal-title":"Journal of Psychedelic Studies"},{"key":"10.1016\/j.jsat.2021.108717_bb0155","doi-asserted-by":"crossref","first-page":"61","DOI":"10.2147\/SAR.S50807","article-title":"Clinical potential of methylphenidate in the treatment of cocaine addiction: A review of the current evidence","volume":"6","author":"D\u00fcrsteler","year":"2015","journal-title":"Substance Abuse and Rehabilitation"},{"key":"10.1016\/j.jsat.2021.108717_bb0160","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1016\/S0099-9598(01)56017-4","article-title":"\u201cReturning to the path\u201d: The use of iboga[ine] in an equatorial African ritual context and the binding of time, space, and social relationships","volume":"56","author":"Fernandez","year":"2001","journal-title":"The Alkaloids. Chemistry and Biology"},{"key":"10.1016\/j.jsat.2021.108717_bb0165","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1016\/j.jep.2016.05.022","article-title":"Effects of low dose ibogaine on subjective mood state and psychological performance","volume":"189","author":"Forsyth","year":"2016","journal-title":"Journal of Ethnopharmacology"},{"key":"10.1016\/j.jsat.2021.108717_bb0170","series-title":"Handbook of Experimental Pharmacology","doi-asserted-by":"crossref","first-page":"249","DOI":"10.1007\/164_2017_71","article-title":"SLC6 transporter folding diseases and pharmacochaperoning","volume":"245","author":"Freissmuth","year":"2018"},{"issue":"3","key":"10.1016\/j.jsat.2021.108717_bb0175","first-page":"232","article-title":"Safety, pharmacokinetic, and pharmacodynamic evaluation of a noribogaine multiple-dose regimen in opioid-dependent subjects","volume":"26","author":"Geoffroy","year":"2017","journal-title":"The American Journal on Addictions"},{"issue":"9","key":"10.1016\/j.jsat.2021.108717_bb0180","doi-asserted-by":"crossref","first-page":"2013","DOI":"10.1097\/00001756-200006260-00041","article-title":"18-MC reduces methamphetamine and nicotine self-administration in rats","volume":"11","author":"Glick","year":"2000","journal-title":"Neuroreport"},{"issue":"1\u20132","key":"10.1016\/j.jsat.2021.108717_bb0185","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1016\/S0014-2999(02)01284-0","article-title":"Antagonism of alpha 3 beta 4 nicotinic receptors as a strategy to reduce opioid and stimulant self-administration","volume":"438","author":"Glick","year":"2002","journal-title":"European Journal of Pharmacology"},{"key":"10.1016\/j.jsat.2021.108717_bb0190","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1016\/S0099-9598(01)56006-X","article-title":"Mechanisms of action of ibogaine: Relevance to putative therapeutic effects and development of a safer iboga alkaloid congener","volume":"56","author":"Glick","year":"2001","journal-title":"The Alkaloids. Chemistry and Biology"},{"issue":"6","key":"10.1016\/j.jsat.2021.108717_bb0195","doi-asserted-by":"crossref","first-page":"460","DOI":"10.1002\/cpdd.254","article-title":"Ascending single-dose, double-blind, placebo-controlled safety study of noribogaine in opioid-dependent patients","volume":"5","author":"Glue","year":"2016","journal-title":"Clinical Pharmacology in Drug Development"},{"issue":"2","key":"10.1016\/j.jsat.2021.108717_bb0200","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1002\/jcph.404","article-title":"Ascending-dose study of noribogaine in healthy volunteers: Pharmacokinetics, pharmacodynamics, safety, and tolerability","volume":"55","author":"Glue","year":"2015","journal-title":"Journal of Clinical Pharmacology"},{"issue":"6","key":"10.1016\/j.jsat.2021.108717_bb0205","doi-asserted-by":"crossref","first-page":"680","DOI":"10.1002\/jcph.471","article-title":"Influence of CYP2D6 activity on the pharmacokinetics and pharmacodynamics of a single 20 mg dose of ibogaine in healthy volunteers","volume":"55","author":"Glue","year":"2015","journal-title":"Journal of Clinical Pharmacology"},{"issue":"1","key":"10.1016\/j.jsat.2021.108717_bb0210","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1186\/s12906-017-1562-1","article-title":"Antiviral effect of compounds derived from the seeds of Mammea americana and Tabernaemontana cymosa on dengue and chikungunya virus infections","volume":"17","author":"G\u00f3mez-Calder\u00f3n","year":"2017","journal-title":"BMC Complementary and Alternative Medicine"},{"issue":"4","key":"10.1016\/j.jsat.2021.108717_bb0215","doi-asserted-by":"crossref","first-page":"e99","DOI":"10.1016\/j.jemermed.2019.06.052","article-title":"Ibogaine consumption with seizure-like episodes, QTc-prolongation, and captured cardiac dysrhythmias","volume":"57","author":"Grogan","year":"2019","journal-title":"Journal of Emergency Medicine"},{"key":"10.1016\/j.jsat.2021.108717_bb0220","author":"Health and Disability Commissioner"},{"issue":"March","key":"10.1016\/j.jsat.2021.108717_bb0225","first-page":"1","article-title":"Examination of the phenomenology of the ibogaine treatment experience: Role of altered states of consciousness and psychedelic experiences","volume":"1072","author":"Heink","year":"2017","journal-title":"Journal of Psychoactive Drugs"},{"key":"10.1016\/j.jsat.2021.108717_bb0230","doi-asserted-by":"crossref","DOI":"10.3389\/fphar.2021.640241","article-title":"Low doses of psilocybin and ketamine enhance motivation and attention in poor performing rats: Evidence for an antidepressant property","volume":"12","author":"Higgins","year":"2021","journal-title":"Frontiers in Pharmacology"},{"issue":"5","key":"10.1016\/j.jsat.2021.108717_bb0235","doi-asserted-by":"crossref","first-page":"659","DOI":"10.1097\/JCP.0b013e31822c6509","article-title":"Ibogaine-associated psychosis in schizophrenia: a case report","volume":"31","author":"Houenou","year":"2011","journal-title":"Journal of Clinical Psychopharmacology"},{"issue":"2","key":"10.1016\/j.jsat.2021.108717_bb0240","doi-asserted-by":"crossref","first-page":"420","DOI":"10.1021\/ja078192m","article-title":"Direct coupling of catharanthine and vindoline to provide vinblastine: Total synthesis of (+)- and ent-(-)-vinblastine","volume":"130","author":"Ishikawa","year":"2008","journal-title":"Journal of the American Chemical Society"},{"issue":"8","key":"10.1016\/j.jsat.2021.108717_bb0245","doi-asserted-by":"crossref","first-page":"975","DOI":"10.1248\/yakushi.129.975","article-title":"Chemical and DNA analyses for the products of a psychoactive plant, voacanga africana","volume":"129","author":"Kikura-Hanajiri","year":"2009","journal-title":"Yakugaku Zasshi"},{"key":"10.1016\/j.jsat.2021.108717_bb0250","series-title":"Phytochemistry","article-title":"Progress in the chemistry of organic natural products 105","volume":"105","author":"Kinghorn","year":"2017"},{"key":"10.1016\/j.jsat.2021.108717_bb0255","series-title":"Molecules","first-page":"2208","article-title":"The anti-addiction drug ibogaine and the heart: A delicate relation","volume":"20","author":"Koenig","year":"2015"},{"issue":"2","key":"10.1016\/j.jsat.2021.108717_bb0260","doi-asserted-by":"crossref","first-page":"237","DOI":"10.1111\/j.1369-1600.2012.00447.x","article-title":"Anti-addiction drug ibogaine inhibits hERG channels: A cardiac arrhythmia risk","volume":"19","author":"Koenig","year":"2014","journal-title":"Addiction Biology"},{"issue":"1","key":"10.1016\/j.jsat.2021.108717_bb0265","first-page":"21","article-title":"Ibogaine in the 21st century: Boosters, tune-ups and maintenance","volume":"15","author":"Kroupa","year":"2005","journal-title":"Maps"},{"issue":"9","key":"10.1016\/j.jsat.2021.108717_bb0270","doi-asserted-by":"crossref","first-page":"1039","DOI":"10.1177\/0269881119857204","article-title":"Microdosing psychedelics: More questions than answers? An overview and suggestions for future research","volume":"33","author":"Kuypers","year":"2019","journal-title":"Journal of Psychopharmacology"},{"key":"10.1016\/j.jsat.2021.108717_bb0275","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1007\/978-3-319-49712-9_2","article-title":"The iboga alkaloids","volume":"105","author":"Lavaud","year":"2017","journal-title":"Progress in the Chemistry of Organic Natural Products"},{"issue":"December 2016","key":"10.1016\/j.jsat.2021.108717_bb0280","doi-asserted-by":"crossref","first-page":"309","DOI":"10.1016\/j.drugalcdep.2018.06.038","article-title":"Pharmacotherapy for amphetamine dependence: A systematic review","volume":"191","author":"Lee","year":"2018","journal-title":"Drug and Alcohol Dependence"},{"issue":"4","key":"10.1016\/j.jsat.2021.108717_bb0285","doi-asserted-by":"crossref","first-page":"297","DOI":"10.3109\/15563650.2016.1138226","article-title":"How toxic is ibogaine?","volume":"54","author":"Litjens","year":"2016","journal-title":"Clinical Toxicology (Philadelphia, Pa.)"},{"key":"10.1016\/j.jsat.2021.108717_bb0290","doi-asserted-by":"crossref","first-page":"293","DOI":"10.1016\/S0099-9598(01)56020-4","article-title":"Case studies of ibogaine treatment: Implications for patient management strategies","volume":"56","author":"Lotsof","year":"2001","journal-title":"The Alkaloids. Chemistry and Biology"},{"issue":"1","key":"10.1016\/j.jsat.2021.108717_bb0295","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1111\/j.1521-0391.1998.tb00472.x","article-title":"Observations on treatment with ibogaine","volume":"7","author":"Luciano","year":"1998","journal-title":"The American journal on addictions"},{"issue":"3","key":"10.1016\/j.jsat.2021.108717_bb0300","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1177\/0960327107087802","article-title":"Ibogaine, an anti-addictive drug: Pharmacology and time to go further in development. A narrative review","volume":"27","author":"Ma\u010diulaitis","year":"2008","journal-title":"Human and Experimental Toxicology"},{"key":"10.1016\/j.jsat.2021.108717_bb0305","doi-asserted-by":"crossref","first-page":"675","DOI":"10.1016\/j.neuropharm.2015.08.032","article-title":"Noribogaine is a G-protein biased kappa-opioid receptor agonist","volume":"99","author":"Maillet","year":"2015","journal-title":"Neuropharmacology"},{"issue":"3","key":"10.1016\/j.jsat.2021.108717_bb0310","doi-asserted-by":"crossref","first-page":"256","DOI":"10.1080\/02791072.2018.1447175","article-title":"Changes in withdrawal and craving scores in participants undergoing opioid detoxification utilizing ibogaine","volume":"50","author":"Malcolm","year":"2018","journal-title":"Journal of Psychoactive Drugs"},{"issue":"3","key":"10.1016\/j.jsat.2021.108717_bb0315","doi-asserted-by":"crossref","first-page":"203","DOI":"10.1111\/ajad.12209","article-title":"Mania following use of ibogaine: A case series","volume":"24","author":"Marta","year":"2015","journal-title":"The American Journal on Addictions"},{"issue":"1","key":"10.1016\/j.jsat.2021.108717_bb0320","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1080\/00952990.2017.1357184","article-title":"Breaking the cycle of opioid use disorder with ibogaine","volume":"44","author":"Mash","year":"2018","journal-title":"American Journal of Drug and Alcohol Abuse"},{"key":"10.1016\/j.jsat.2021.108717_bb0325","first-page":"9(JUN).","article-title":"Ibogaine detoxification transitions opioid and cocaine abusers between dependence and abstinence: Clinical observations and treatment outcomes","author":"Mash","year":"2018","journal-title":"Frontiers in pharmacology"},{"key":"10.1016\/j.jsat.2021.108717_bb0330","series-title":"Chemistry and Biology","first-page":"155","article-title":"Ibogaine in the treatment of heroin withdrawal. The alkaloids","volume":"56","author":"Mash","year":"2001"},{"key":"10.1016\/j.jsat.2021.108717_bb0335","doi-asserted-by":"crossref","first-page":"394","DOI":"10.1111\/j.1749-6632.2000.tb05213.x","article-title":"Ibogaine: Complex pharmacokinetics, concerns for safety, and preliminary efficacy measures","volume":"914","author":"Mash","year":"2000","journal-title":"Annals of the New York Academy of Sciences"},{"issue":"7","key":"10.1016\/j.jsat.2021.108717_bb0340","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pmed.1000097","article-title":"Preferred reporting items for systematic reviews and meta-analyses: The PRISMA statement","volume":"6","author":"Moher","year":"2009","journal-title":"PLoS Medicine"},{"key":"10.1016\/j.jsat.2021.108717_bb0345","series-title":"Cocaine","year":"2018"},{"issue":"1","key":"10.1016\/j.jsat.2021.108717_bb0355","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1080\/00952990.2017.1310218","article-title":"Ibogaine treatment outcomes for opioid dependence from a twelve-month follow-up observational study","volume":"44","author":"Noller","year":"2018","journal-title":"American Journal of Drug and Alcohol Abuse"},{"issue":"8","key":"10.1016\/j.jsat.2021.108717_bb0360","first-page":"764","article-title":"Cytochrome P4502D6 catalyzes the O-demethylation of the psychoactive alkaloid ibogaine to 12-hydroxyibogamine","volume":"26","author":"Obach","year":"1998","journal-title":"Drug Metabolism and Disposition: The Biological Fate of Chemicals"},{"issue":"2\u20133","key":"10.1016\/j.jsat.2021.108717_bb0365","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1016\/j.ejphar.2004.03.062","article-title":"Novel iboga alkaloid congeners block nicotinic receptors and reduce drug self-administration","volume":"492","author":"Pace","year":"2004","journal-title":"European Journal of Pharmacology"},{"issue":"March","key":"10.1016\/j.jsat.2021.108717_bb0370","first-page":"1","article-title":"Opioid agonist treatment and risk of mortality during opioid overdose public health emergency: Population based retrospective cohort study","volume":"368","author":"Pearce","year":"2020","journal-title":"The BMJ"},{"key":"10.1016\/j.jsat.2021.108717_bb0375","series-title":"Foundations of understanding, tobacco, alcohol, cannabinoids and opioids","article-title":"Neuropathology of drug addictions and substance misuse","volume":"1","author":"Preedy","year":"2016"},{"issue":"1","key":"10.1016\/j.jsat.2021.108717_bb0380","first-page":"003","article-title":"Ibogaine effect on cocaine craving and use in dependent patients - A double-blind, placebo-controlled pilot study","volume":"1","author":"Prior","year":"2014","journal-title":"Journal of Addiction Therapy"},{"issue":"2","key":"10.1016\/j.jsat.2021.108717_bb0385","article-title":"Psychedelics and the Human Receptorome","volume":"5","author":"Ray","year":"2010"},{"key":"10.1016\/j.jsat.2021.108717_bb0390","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1016\/j.pbb.2016.10.010","article-title":"Acute oral 18-methoxycoronaridine (18-MC) decreases both alcohol intake and IV nicotine self-administration in rats","volume":"150\u2013151","author":"Rezvani","year":"2016","journal-title":"Pharmacology Biochemistry and Behavior"},{"issue":"S1","key":"10.1016\/j.jsat.2021.108717_bb0395","doi-asserted-by":"crossref","first-page":"S10","DOI":"10.1016\/j.eurpsy.2016.01.799","article-title":"Treatment of heroin dependence with ibogaine","volume":"33","author":"Schellekens","year":"2016","journal-title":"European Psychiatry"},{"issue":"11","key":"10.1016\/j.jsat.2021.108717_bb0400","doi-asserted-by":"crossref","first-page":"993","DOI":"10.1177\/0269881114552713","article-title":"Treating drug dependence with the aid of ibogaine: A retrospective study","volume":"28","author":"Schenberg","year":"2014","journal-title":"Journal of Psychopharmacology (Oxford, England)"},{"key":"10.1016\/j.jsat.2021.108717_bb0405","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.drugalcdep.2016.07.005","article-title":"Ibogaine for treating drug dependence. What is a safe dose?","volume":"166","author":"Schep","year":"2016","journal-title":"Drug and Alcohol Dependence"},{"issue":"4","key":"10.1016\/j.jsat.2021.108717_bb0410","doi-asserted-by":"crossref","first-page":"379","DOI":"10.1016\/0740-5472(94)90049-3","article-title":"A preliminary investigation of ibogaine: Case reports and recommendations for further study","volume":"11","author":"Sheppard","year":"1994","journal-title":"Journal of Substance Abuse Treatment"},{"issue":"4","key":"10.1016\/j.jsat.2021.108717_bb0415","doi-asserted-by":"crossref","first-page":"455","DOI":"10.1002\/joa3.12061","article-title":"Cardiac arrest after ibogaine intoxication","volume":"34","author":"Steinberg","year":"2018","journal-title":"Journal of Arrhythmia"},{"key":"10.1016\/j.jsat.2021.108717_bb0420","series-title":"Legal status of ibogaine by country","author":"Wikipedia","year":"2021"},{"issue":"1","key":"10.1016\/j.jsat.2021.108717_bb0425","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1556\/2054.01.2017.005","article-title":"Detoxification from methadone using low, repeated, and increasing doses of ibogaine: A case report","volume":"1","author":"Wilkins","year":"2017","journal-title":"Journal of Psychedelic Studies"},{"key":"10.1016\/j.jsat.2021.108717_bb0430","article-title":"Novel treatment of opioid use disorder using ibogaine and iboga in two adults","volume":"1\u20137","author":"Wilson","year":"2020","journal-title":"Journal of Psychedelic Studies"},{"issue":"2","key":"10.1016\/j.jsat.2021.108717_bb0435","doi-asserted-by":"crossref","first-page":"101","DOI":"10.2174\/1874473708666150107120011","article-title":"Psychedelics as medicines for substance abuse rehabilitation: Evaluating treatments with LSD, peyote, ibogaine and ayahuasca","volume":"7","author":"Winkelman","year":"2014","journal-title":"Current Drug Abuse Reviews"},{"issue":"July","key":"10.1016\/j.jsat.2021.108717_bb0440","article-title":"Adaptation of contingency management for stimulant use disorder during the COVID-19 pandemic","volume":"118","author":"Zastepa","year":"2020","journal-title":"Journal of Substance Abuse Treatment"}],"container-title":["Journal of Substance Abuse Treatment"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0740547221004438?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0740547221004438?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,9]],"date-time":"2025-10-09T19:56:42Z","timestamp":1760039802000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0740547221004438"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,7]]},"references-count":87,"alternative-id":["S0740547221004438"],"URL":"https:\/\/doi.org\/10.1016\/j.jsat.2021.108717","relation":{},"ISSN":["0740-5472"],"issn-type":[{"value":"0740-5472","type":"print"}],"subject":[],"published":{"date-parts":[[2022,7]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"A systematic literature review of clinical trials and therapeutic applications of ibogaine","name":"articletitle","label":"Article Title"},{"value":"Journal of Substance Abuse Treatment","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jsat.2021.108717","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2022 The Authors. Published by Elsevier Inc.","name":"copyright","label":"Copyright"}],"article-number":"108717"}}